In Japan, the use of a drug based on induced pluripotent stem cells for the treatment of Parkinson's disease has been partially permitted. This was reported by the Institute for the Study and Application of iPS Cells at Kyoto University.
The director of the institute, Jun Takahashi, assessed this achievement as a huge step in the field of medicine. He emphasized that all possibilities will be mobilized so that this treatment method will become a reliable standard in the near future.
The new drug contains nerve cells grown from iPS-cells. They are transplanted into the brain of a patient with Parkinson's disease.
Clinical trials conducted in April 2024 showed positive changes in the patients' condition. Experts assess the results as encouraging.
Sumitomo Pharma, the manufacturer of the drug, applied to register it under the Amshepuri trademark. The documents were reviewed in an expedited manner.
A drug for treating ischemic cardiomyopathy, developed on the basis of similar cells, has also been partially approved. The report notes that both drugs are currently the only ones in the world.
Read “Zamin” on Telegram!
